Jump to Main Content
Activation of growth hormone releasing hormone (GHRH) receptor stimulates cardiac reverse remodeling after myocardial infarction (MI)
- Kanashiro-Takeuchi, Rosemeire M., Takeuchi, Lauro M., Rick, Ferenc G., Dulce, Raul, Treuer, Adriana V., Florea, Victoria, Rodrigues, Claudia O., Paulino, Ellena C., Hatzistergos, Konstantinos E., Selem, Sarah M., Gonzalez, Daniel R., Block, Norman L., Schally, Andrew V., Hare, Joshua M.
- Proceedings of the National Academy of Sciences of the United States of America 2012 v.109 no.2 pp. 559-563
- antagonists, cardiac output, cardiomyocytes, echocardiography, fluorescent antibody technique, heart, infarction, insulin-like growth factor I, mitosis, morphometry, myocardial infarction, rats, reverse transcriptase polymerase chain reaction, somatoliberin, somatotropin, stem cells, therapeutics
- Both cardiac myocytes and cardiac stem cells (CSCs) express the receptor of growth hormone releasing hormone (GHRH), activation of which improves injury responses after myocardial infarction (MI). Here we show that a GHRH-agonist (GHRH-A; JI-38) reverses ventricular remodeling and enhances functional recovery in the setting of chronic MI. This response is mediated entirely by activation of GHRH receptor (GHRHR), as demonstrated by the use of a highly selective GHRH antagonist (MIA-602). One month after MI, animals were randomly assigned to receive: placebo, GHRH-A (JI-38), rat recombinant GH, MIA-602, or a combination of GHRH-A and MIA-602, for a 4-wk period. We assessed cardiac performance and hemodynamics by using echocardiography and micromanometry derived pressure-volume loops. Morphometric measurements were carried out to determine MI size and capillary density, and the expression of GHRHR was assessed by immunofluorescence and quantitative RT-PCR. GHRH-A markedly improved cardiac function as shown by echocardiographic and hemodynamic parameters. MI size was substantially reduced, whereas myocyte and nonmyocyte mitosis was markedly increased by GHRH-A. These effects occurred without increases in circulating levels of growth hormone and insulin-like growth factor I and were, at least partially, nullified by GHRH antagonism, confirming a receptor-mediated mechanism. GHRH-A stimulated CSCs proliferation ex vivo, in a manner offset by MIA-602. Collectively, our findings reveal the importance of the GHRH signaling pathway within the heart. Therapy with GHRH-A although initiated 1 mo after MI substantially improved cardiac performance and reduced infarct size, suggesting a regenerative process. Therefore, activation of GHRHR provides a unique therapeutic approach to reverse remodeling after MI.